PerkinElmer Expands Presence In Asia With Acquisition Of SYM-BIO
This article was originally published in PharmAsia News
Executive Summary
PerkinElmer's acquisition of Shanghai-based diagnostics company SYM-BIO for $63.7 million will enhance the firm's diagnostics market position in China
You may also be interested in...
PerkinElmer On R&D Expansion In Singapore: An Interview With PharmAsia News (Part 2 of 2)
PerkinElmer expanded its R&D presence by opening a new Center of Excellence in Singapore March 26. PerkinElmer VP and Chief Scientific Officer Daniel Marshak talked with PharmAsia News from Singapore the following day about the expansion and the company's growing footprint in Asia. Marshak is responsible for setting the strategic direction of PerkinElmer's research and development functions. He joined the company in 2006, after serving as VP and chief technology officer of Cambrex Corp.
PerkinElmer On R&D Expansion In Singapore: An Interview With PharmAsia News (Part 1 of 2)
PerkinElmer expanded its R&D presence by opening a new Center of Excellence in Singapore March 26. PerkinElmer VP and Chief Scientific Officer Daniel Marshak talked with PharmAsia News from Singapore the following day about the expansion and the company's growing footprint in Asia. Marshak is responsible for setting the strategic direction of PerkinElmer's research and development functions. He joined the company in 2006, after serving as VP and chief technology officer of Cambrex Corp.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).